NutriBand (NTRB) Return on Capital Employed (2017 - 2026)
NutriBand (NTRB) posted Return on Capital Employed of 127.72% for Q2 2026, down 10.54% sequentially from 115.54% in Q1 2026, and up 3893.0% YoY from 3.2% in Q2 2025.
NutriBand (NTRB) Return on Capital Employed (2017 - 2026) Analysis & Trends
NutriBand has reported Return on Capital Employed for 10 years, with the latest figure at 127.72% in Q2 2026.
- Quarterly Return on Capital Employed rose 3893.0% year-over-year to 127.72% in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 127.72% (up 3893.0% YoY) and the FY2026 annual result came in at 123.69%, up 3427.0% from the prior year.
- Return on Capital Employed declined to 127.72% in Q2 2026 per NTRB's latest filing, from 115.54% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 45.92% in Q1 2022 and troughed at 166.65% in Q2 2025.
- A 5-year average of 83.97% and a median of 63.02% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 11017 bps in 2025, then soared 3893 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 64.14% in 2022, then climbed by 3 bps to 61.9% in 2023, then rose by 18 bps to 50.95% in 2024, then sank by 196 bps to 150.8% in 2025, then climbed by 15 bps to 127.72% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 127.72%, 115.54%, and 150.8% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | NutriBand | 46.38 Mn | 42.37 Mn | 196,801.00 | -127.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -127.72% |
| Jan 31, 2026 | -115.54% |
| Oct 31, 2025 | -150.80% |
| Jul 31, 2025 | -157.79% |
| Apr 30, 2025 | -166.65% |
| Jan 31, 2025 | -113.98% |
| Oct 31, 2024 | -50.95% |
| Jul 31, 2024 | -47.62% |
| Apr 30, 2024 | -57.90% |
| Jan 31, 2024 | -69.39% |
| Oct 31, 2023 | -61.90% |
| Jul 31, 2023 | -54.73% |
| Apr 30, 2023 | -58.05% |
| Jan 31, 2023 | -48.05% |
| Oct 31, 2022 | -64.14% |
| Jul 31, 2022 | -64.64% |
| Apr 30, 2022 | -55.69% |
| Jan 31, 2022 | -45.92% |
| Oct 31, 2021 | -38.30% |
| Jul 31, 2021 | -39.18% |